Predict your next investment

IncellDx company logo
Corporation
HEALTHCARE | Disease Diagnosis
incelldx.com

See what CB Insights has to offer

Stage

Series A - II | Alive

Total Raised

$9M

Last Raised

$6M | 10 yrs ago

About IncellDx

InCellDx focuses on the detection and monitoring of life-threatening diseases such as cervical cancer, breast cancer, HIV/AIDs, hepatitis and organ transplant rejection. The company's technology enables quantification of molecular biomarkers inside intact cells using cell-based instruments and in-situ hybridization. This process allows protein and gene expression to be measured by distinct cell type, aiding in both diagnosis and disease localization.

IncellDx Headquarter Location

1700 EL Camino Real

Menlo Park, California, 94027,

United States

650-777-7630

Latest IncellDx News

IncellDx Awarded Patent for Use of CCR5 Antagonist Maraviroc in Treatment of COVID-19

Nov 23, 2021

Additional patents directed to the use of CCR5 antagonists pending November 23, 2021 11:11 AM Eastern Standard Time SAN CARLOS, Calif.--( BUSINESS WIRE )--IncellDx today announced it has been granted U.S. Patent No. 11,180, 491 by the U.S. Patent and Trademark Office (“USPTO”) for methods of treating coronaviruses including COVID-19 (the “Patent”). This patent underwent expedited review under the USPTO’s COVID-19 Prioritized Examination Pilot Program. The patent is supported by IncellDx’s studies on the role of CCR5 antagonism in acute COVID-19 and in chronic COVID, also known as long COVID or post-acute sequelae of COVID-19 (PASC). In these studies, including a recent study published in the International Journal of Infectious Diseases, among others, IncellDx demonstrated that CCR5 antagonism normalized immunologic biomarkers such as cytokines and signaling proteins and also restored levels of immune cell subsets. IncellDx’s Chronic COVID Treatment Center recently partnered with ARISE MD Integrative Medicine & Surgery to clinically evaluate the role of CCR5 antagonists in a randomized, placebo controlled trial as a novel therapeutic approach to treating chronic COVID. “IncellDx is a pioneer in deploying precision medicine approaches in infectious disease,” said Bruce Patterson, CEO, IncellDx. “Our aim is to develop and apply objective diagnostic criteria, new technologies, and more effective treatment approaches that address the underlying causes of acute and chronic COVID-19.” About IncellDx IncellDx is a precision medicine company advancing novel diagnostics and prognostics to better understand and treat infectious disease and cancer. The company’s innovative technology platform enables simultaneous cell classification and single cell analysis of proteomic and genomic biomarkers. The company launched the Chronic COVID Treatment Center to apply precision medicine approaches to evaluate, characterize and more effectively address chronic COVID. Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing IncellDx

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

IncellDx is included in 2 Expert Collections, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

IncellDx Patents

IncellDx has filed 18 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Infectious causes of cancer
  • Oncology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/9/2020

11/23/2021

Cytokines, Clusters of differentiation, Chemokine receptors, Monoclonal antibodies, Transcription factors

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

10/9/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

11/23/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Cytokines, Clusters of differentiation, Chemokine receptors, Monoclonal antibodies, Transcription factors

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

IncellDx Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

IncellDx Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.